Thymol Composition for Intestinal Disease via Endocannabinoid Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and functional intestinal diseases in humans and monogastric animals, such as Crohn's disease and irritable bowel syndrome, often fail to provide a complete and lasting resolution and are associated with unwanted side effects, limiting their use.
Innovation Solution
A composition comprising thymol, which modulates the endocannabinoid system receptors and enzymes, such as CB1 and CB2, and gut chemosensing markers like TRPV1 and OR1G1, formulated with a controlled release lipid matrix for targeted intestinal release, offering a therapeutic approach without significant side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs or compounds are used to treat inflammatory or functional intestinal diseases, then some therapeutic effect is achieved, but the treatment does not allow complete and/or lasting resolution and produces unwanted side effects
Solution Approach 1:
The patent employs thymol, a natural compound from Thymus vulgaris essential oil, as a short-acting therapeutic agent that can be administered repeatedly without accumulating harmful effects. Thymol acts as a temporary but effective intervention that modulates the endocannabinoid system without the long-term side effects associated with conventional medications like NSAIDs or corticosteroids.
Solution Approach 2:
The invention changes the chemical parameter of the treatment by using thymol (a phenolic compound) instead of conventional pharmaceuticals. This chemical substitution alters the mechanism of action to work through endocannabinoid system modulation rather than direct anti-inflammatory or immunosuppressive pathways, thereby achieving therapeutic effects with fewer side effects.
2Reliability
If thymol is administered to modulate the endocannabinoid system, then complete and lasting resolution of intestinal diseases is achieved, but rapid absorption in the stomach may reduce effectiveness
Solution Approach 1:
The patent introduces a lipid-based delivery system as an intermediary carrier for thymol. This lipid vehicle protects thymol from premature gastric absorption and facilitates its targeted delivery to the intestinal tract, where it can effectively modulate the endocannabinoid system. The lipid matrix acts as a mediator that preserves thymol integrity until it reaches the site of action.
Solution Approach 2:
The invention uses a lipid-based encapsulation system that forms a protective shell around thymol molecules. This flexible lipid matrix protects thymol from degradation and premature absorption in the stomach, allowing controlled release in the intestinal tract where it can exert its therapeutic effect on the endocannabinoid system.
Data Source
AI summary
The present invention relates to compositions comprising thymol for use in the preventive and/or curative treatment of inflammatory or functional diseases of the intestinal tract and related symptoms in human subjects, or monogastric animals, or poultry or fish by modulating the receptors and/or enzymes of the endocannabinoid system.